SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.810
+0.190 (5.25%)
At close: Aug 25, 2026, 4:00 PM EDT
3.810
0.00 (0.00%)
After-hours: Aug 25, 2026, 4:04 PM EDT
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $346.66 million as of August 25, 2026. Its market cap has increased by 1,417.30% in one year.
Market Cap
346.66M
Enterprise Value
249.16M
1-Year Change
1,417.30%
Ranking
Category
Stock Price
$3.81
ChartMarket Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $346.66M, an increase of 165.12%. That is a compound annual growth rate of 19.23%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 25, 2026 | 346.66M | 94.70% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| DiaMedica Therapeutics | 350.79M |
| Agenus | 347.56M |
| Sutro Biopharma | 347.21M |
| Abeona Therapeutics | 346.54M |
| ProQR Therapeutics | 342.93M |
| Opus Genetics | 340.69M |
| Immuneering | 339.66M |
| YD Bio | 330.50M |